Stocks
Guardant Health, Inc.GH
NASDAQHealthcareBiotechnology$85.49+1.75%
A precision oncology company focused on blood-based cancer diagnostics, Guardant Health develops liquid biopsy tests for early detection and treatment selection. Its flagship Guardant360 test analyzes circulating tumor DNA to guide therapy decisions, positioning it as a key player in the growing liquid biopsy market. Investors monitor its commercial adoption and pipeline progress in competing with tissue biopsy standards.
Market Cap: $11.2B52W Range: $36.36 – $120.74
Congressional Interest in Guardant Health, Inc. (GH)
4 members of Congress have disclosed 14 trades in Guardant Health, Inc. (GH), a Healthcare company. The buy/sell breakdown shows 7 purchases versus 7 sales. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
14
Unique Politicians
4
Buys
7
Sells
7
Who in Congress Is Trading GH?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-11-21 | Sheldon Whitehouse | buy | $1K – $15K |
| 2022-06-03 | Rohit Khanna | buy | $1K – $15K |